{"id":963455,"date":"2026-05-15T09:23:04","date_gmt":"2026-05-15T13:23:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/"},"modified":"2026-05-15T09:23:04","modified_gmt":"2026-05-15T13:23:04","slug":"briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/","title":{"rendered":"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>BriaCell expands push in women\u2019s health, building on Phase 2 success in advanced metastatic breast cancer<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Bria-OVA+, BriaCell\u2019s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity <\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, May  15, 2026  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer.<\/p>\n<p align=\"justify\">\u201cFollowing the encouraging efficacy and tolerability data from BriaCell\u2019s Phase 2 study in metastatic breast cancer, we are expanding our pipeline to include cell-based immunotherapy candidates for gynecologic cancers beginning with ovarian,\u201d stated Dr. William V. Williams, BriaCell\u2019s President &amp; CEO. \u201cBria-OVA+ reflects our broader strategy to build on the Bria-OTS+\u2122 platform and advance next-generation personalized immunotherapies for difficult-to-treat cancers and become a leader in women\u2019s health.\u201d<\/p>\n<p align=\"justify\">\u201cOvarian cancer remains the deadliest gynecologic cancer, and patients who do not respond to available therapies continue to face serious unmet medical need,\u201d stated Dr. Giuseppe Del Priore, BriaCell\u2019s Chief Medical Officer, and a Key Opinion Leader in ovarian cancer. \u201cWe believe Bria-OVA+ has the potential to provide a differentiated immunotherapeutic approach for ovarian cancer patients with limited treatment options.\u201d<\/p>\n<p align=\"justify\">BriaCell recently reported preclinical data for Bria-BRES+\u2122, its next-generation breast cancer immunotherapy candidate derived from the same Bria-OTS+ platform. In a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SivrdfN05VQaB90Tzec6F5bKGJBvaji2-VYuS9fUMjAQ5w86zrtbBCdIOUPHMglYkBQQqWtYqVVh4o1lSu0dC9nTQO0jqtP7xzrhRY8bfZ70peb1gcoYh75sypGbgxNjP-V5VQphvgi5egNozK1DfETk4ViQoysEoOtYQQJQB_VdiEOu9d1YBoH_NGfkTUcA\" rel=\"nofollow\" target=\"_blank\">recent AACR poster<\/a> presentation, Bria-BRES+ demonstrated activation of both adaptive and innate immunity, including na\u00efve\/resting T cells, dendritic cells, and natural killer (NK) cells. BriaCell believes this multipronged immune activation supports the potential of the Bria-OTS+ platform to generate anti-tumor immune responses and may help inform the development of Bria-OVA+ for ovarian cancer.<\/p>\n<p align=\"justify\">BriaCell has licensed ovarian cancer cell-lines from American Type Culture Collection (ATCC) and has commenced development activities to support production of Bria-OVA+ for potential clinical use.<\/p>\n<p align=\"justify\">\n        <strong>Ovarian Cancer Facts<\/strong>\n      <\/p>\n<p align=\"justify\">According to National Cancer Institute, an estimated 21,010 women in the U.S. will be diagnosed with ovarian cancer, and approximately 12,450 will die from the disease in 2026. Ovarian cancer remains the deadliest gynecologic cancer. It is inherited or acquired abnormal BRCA gene. Treatments include surgery to remove the tumor\/s, platinum-based chemotherapy, ELAHERE, a folate receptor alpha (FR\u03b1)-directed antibody and microtubule inhibitor conjugate, and LYNPARZA, a poly (ADP-ribose) polymerase inhibitor, also referred to as a PARP inhibitor. However, many patients do not respond to these treatments and are often associated with harsh side effects.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7Tc-NFOi-JdOScwxxYPr6u-eqeWNnf5WOtvkU0xm7hnivTP-7BD22kIJyrFAioK2h_LO6D2mf-LrRh-O5lAyNVfYE2wM6R9QqDOCmlKJZ6M=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those regarding the development of Bria-OVA+, its potential clinical use in ovarian cancer, expectations regarding its immune\u2011stimulating design and anti\u2011tumor activity, pipeline expansion building on Phase 2 data, and expectations regarding the potential clinical benefits of the Bria\u2011OTS+ platform, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company&#8217;s most recent Management\u2019s Discussion and Analysis, under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company&#8217;s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gjF30MSfm-_-I4smct4nb748GTVkAbEBoGfEdNKfXM99n6RT5a2bLQ4JHRcRLKzt7aOSwG32LBl6GExngZIIamrYQ3iV2b1cLKg8oLZMCV4=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a><\/u><\/strong>\u00a0and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gjF30MSfm-_-I4smct4nb2-ASuuGYwMZWamWTLqDRoKmxWrQOluLu8mMDhDS9feqpRfJJSfmeA-iWino_dYB6w==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=68cFIzUWBAk-g9GqvUqZA5psMzuRRPagLwuJM5irIoBLoGYDd0Cpz0RfQLYwK4wOIF1V-53mBF6k_96GKeOvSl0ORHyrIqMS2krwrnjuWA0=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1VEbzBD3DSYVWBawdCDJ_jgYYSUuGC9YBYYgLyzp-aE_rriiQKNRmqQm21mA-uET5HYQ4M3QOLEL8rbnER29evtYeVGsQYeXJBhn-0HV1gY=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmM1N2Y4NjEtOGEzZS00OWFjLTliOTYtYjcyYjE2NDhmYzIxLTExMDIyMjktMjAyNi0wNS0xNS1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BriaCell expands push in women\u2019s health, building on Phase 2 success in advanced metastatic breast cancer Bria-OVA+, BriaCell\u2019s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S. PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer. \u201cFollowing the encouraging efficacy and tolerability data from BriaCell\u2019s Phase 2 study &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963455","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BriaCell expands push in women\u2019s health, building on Phase 2 success in advanced metastatic breast cancer Bria-OVA+, BriaCell\u2019s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S. PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer. \u201cFollowing the encouraging efficacy and tolerability data from BriaCell\u2019s Phase 2 study &hellip; Continue reading &quot;BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-15T13:23:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122\",\"datePublished\":\"2026-05-15T13:23:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/\"},\"wordCount\":813,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/\",\"name\":\"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg=\",\"datePublished\":\"2026-05-15T13:23:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122 - Market Newsdesk","og_description":"BriaCell expands push in women\u2019s health, building on Phase 2 success in advanced metastatic breast cancer Bria-OVA+, BriaCell\u2019s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S. PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer. \u201cFollowing the encouraging efficacy and tolerability data from BriaCell\u2019s Phase 2 study &hellip; Continue reading \"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-15T13:23:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122","datePublished":"2026-05-15T13:23:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/"},"wordCount":813,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/","name":"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg=","datePublished":"2026-05-15T13:23:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMDg5NyM3NjA0OTE3IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963455"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963455\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}